Cipher Pharmaceuticals Announces the Passing of Director Mr. Harold Wolkin

Cipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a respected member of its Board of Directors and Chairman of the Audit Committee, on August 26, 2025. The company expressed deep sorrow at the loss of Mr. Wolkin, highlighting his significant contributions and active role within the organization. With a profound understanding of capital markets and a strong dedication to governance, Mr. Wolkin was instrumental in guiding Cipher’s strategic initiatives and supporting management throughout his tenure.

His leadership was marked by a commitment to the company's growth and an unwavering integrity that resonated with shareholders and colleagues alike. Known for his stature in the Canadian capital markets community, Mr. Wolkin's professional legacy and personal connections will be deeply felt and missed across the sector.

Craig Mull, the Interim CEO and Chairman of the Board, offered heartfelt condolences on behalf of Cipher's Board, management, and employees, acknowledging Mr. Wolkin as a competent and energetic board member whose meaningful contributions greatly benefited the company. His professionalism and character were held in high regard, reflecting the high standards he set in his roles.

Cipher Pharmaceuticals, listed on the TSX and OTCQX, is a specialty pharmaceutical company focused primarily on dermatology, boasting a diverse portfolio of commercial and developmental products. The company dedicates itself to addressing unmet medical needs through product acquisitions and managing the clinical development and regulatory approval processes. The team at Cipher extends their sympathies to Mr. Wolkin's family and loved ones during this difficult time, as they remember a leader whose impact will continue to resonate within the organization and beyond.

The recent announcement of the passing of Mr. Harold Wolkin, a significant figure on the Board of Directors for Cipher Pharmaceuticals Inc. (TSX: CPH), marks a notable change within the company. As a well-respected member of the Canadian capital markets community and Chairman of the Audit Committee, Mr. Wolkin's expertise and commitment to the company's growth were vital. His departure not only creates a leadership void but also presents both challenges and opportunities for investors.

In the short term, market reactions could be influenced by the abrupt loss of Mr. Wolkin. Investors may feel uncertainty regarding the company’s governance and strategic direction without his guidance. Historically, changes in board composition can lead to fluctuations in stock prices, particularly if the incoming directors lack the same level of experience or industry connections that Mr. Wolkin possessed. Therefore, analysts recommend closely monitoring Cipher's communications for updates on leadership transitions and strategic initiatives.

Long-term investors, however, might see this as an opportunity. Cipher Pharmaceuticals has an established portfolio in dermatology and a strong commitment to filling unmet medical needs in the pharmaceutical landscape. The company's focus on innovation and regulatory approval of various products can continue to drive growth independent of individual board members.

It's essential for stakeholders to assess the incoming leadership carefully. If Cipher can attract qualified individuals with a vision aligned with existing strategic goals, the company's trajectory could remain positively impacted. Investors should consider maintaining their positions while keeping a watchful eye on how the leadership changes unfold.

In summary, while the passing of Mr. Wolkin introduces an element of uncertainty, Cipher’s fundamentals in specialty pharmaceuticals remain strong. It may be prudent for investors to evaluate their strategies, especially in light of potential new governance influences.